Patents by Inventor Helen Romanczuk

Helen Romanczuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adenoviral helper vectors
    Patent number: 6541245
    Abstract: The present invention is directed to improved helper vectors and cell lines for the production of pseudoadenoviral (PAV) vectors containing substantially reduced levels of contaminating helper vector. The invention provides for helper vectors for the production of substantially helper vector-free PAV stocks comprising phag C31 recombinase recognition sequences which, depending upon their arrangement within the helper vector, can prevent helper vector packaging. The invention also provides for improved cell lines for the production of substantially helper vector-free PAV stocks comprising a stably introduced novel circular PAV genome into the cell.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: April 1, 2003
    Assignee: Genzyme Corporation
    Inventors: Helen Romanczuk, Samuel C. Wadsworth, Patricia Berthelette
  • Adenovirus vectors for gene therapy
    Patent number: 5824544
    Abstract: The present invention relates to novel adenovirus vectors for use in gene therapy which are designed to prevent the generation of replication-competent adenovirus (RCA) during in vitro propagation and clinical use. The invention also provides methods for the production of the novel virus vectors. These vectors maximize safety for clinical applications in which adenovirus vectors are used to transfer genes into recipient cells for gene therapy.
    Type: Grant
    Filed: October 6, 1995
    Date of Patent: October 20, 1998
    Assignee: Genzyme Corporation
    Inventors: Donna Armentano, Helen Romanczuk, Samuel Charles Wadsworth
  • Adenovirus vectors for gene therapy
    Patent number: 5707618
    Abstract: The present invention relates to novel adenovirus vectors for use in gene therapy which are designed to prevent the generation of replication-competent adenovirus (RCA) during in vitro propagation and clinical use. The invention also provides methods for the production of the novel virus vectors. These vectors maximize safety for clinical applications in which adenovirus vectors are used to transfer genes into recipient cells for gene therapy.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: January 13, 1998
    Assignee: Genzyme Corporation
    Inventors: Donna Armentano, Helen Romanczuk, Samuel Charles Wadsworth